Testosterone and bone health are connected, which can make the phrase stronger bones sound like a straightforward treatment promise. The evidence needs a more careful reading: bone-density measurements and actual fractures are different outcomes.
If you have low bone density, a previous fracture, or concerns about falls, discuss those directly with a clinician. A testosterone plan should not automatically be treated as a complete osteoporosis or fracture-prevention plan.
- Bone density and fractures are different study outcomes.
- The TRAVERSE fracture study did not demonstrate fracture prevention.
- A bone-health plan may require care beyond TRT.
What a bone-density test measures
A bone mineral density test helps assess the amount of mineral in bone and contributes to evaluating osteoporosis and fracture risk. NIAMS explains how clinicians interpret measures such as T-scores in the appropriate context. The result belongs with age, prior fractures, and other risk information.
A testosterone test does not replace a bone-density assessment. Likewise, a better density measurement does not by itself tell us how many fractures a treatment prevents. Ask what clinical outcome a proposed treatment has been shown to change, rather than assuming every improved marker delivers the same benefit.
What the fracture trial found
A 2024 TRAVERSE subtrial included 5,204 men aged 45–80 with hypogonadism and existing or elevated cardiovascular risk. Participants received testosterone gel or placebo. Over a median 3.19 years, clinical fractures occurred in 3.50% versus 2.46%, respectively. The study did not show fracture prevention with testosterone; fractures were more frequent in the testosterone group.
The population and formulation matter. This result is not a comparison of every TRT product and does not predict an individual’s outcome. It does show why improved bone density should not be converted into a general promise of fewer fractures.
Do not let osteoporosis care disappear into a TRT plan
A clinician assessing bone health may consider prior fractures, medicines, nutrition, physical activity, and fall risk, as well as whether an osteoporosis medicine is indicated. Those questions remain relevant even if testosterone deficiency has also been diagnosed.
Tell the clinician about fractures after relatively minor injuries and difficulties with balance. Ask whether a bone-density test or another evaluation is appropriate for your history. Do not assume that starting hormone treatment means existing bone-health recommendations can be abandoned.
Separate the reason for each prescription
TRT may be considered for an appropriate testosterone-deficiency diagnosis after benefit and risk are discussed. A different medicine may be recommended to address osteoporosis or fracture risk. Ask what evidence supports each purpose, especially if a provider’s marketing groups several potential benefits into one broad promise.
Our TRT after 50 guide explains why age alone does not establish a treatment indication. The monitoring guide covers the ongoing review that any testosterone plan still needs.
Questions to take to the appointment
Ask whether the goal is to treat symptoms of testosterone deficiency, increase bone density, reduce fracture risk, or address more than one problem. Then ask which evidence supports each goal and what additional care is needed. Keep those answers separate in your notes.
Our Marek-versus-Defy comparison illustrates why a broad health assessment needs specific follow-up decisions. A useful plan explains the relationship between the conditions without allowing one treatment to stand in for every other part of care.
Sources & reading notes
Provider pages describe advertised services, not independently verified outcomes. Prices and eligibility may change. Checked September 20, 2026.